Information Provided By:
Fly News Breaks for April 27, 2015
QURE, CLDN
Apr 27, 2015 | 08:55 EDT
Roth Capital said it would be opportunistic buyers of uniQure (QURE) shares if the stock is weak following the failure of a trial for competitor Celladon's (CLDN) gene therapy for heart failure patients, Mydicar. The firm believes uniQure's S100A1 target in its trial is potentially superior to the one used in Celladon's study and the firm thinks uniQure's pipeline is "at the cusp" of significant value creation. Roth reiterates its Buy rating and $38 price target on uniQure shares.
News For QURE;CLDN From the Last 2 Days
QURE
Jun 17, 2019 | 09:15 EDT
HIGHER: Array Biopharma (ARRY), up 59% after agreeing to be acquired by Pfizer (PFE) for $48.00 per share... Aclaris Therapeutics (ACRS), up 9% after announcing results from a Phase 2 open-label clinical trial of ATI-502, an investigational topical Janus Kinase 1/3 inhibitor, in patients with androgenetic alopecia... uniQure (QURE), up 8% after Bloomberg reported the company is exploring options with advisers, including a potential sale or partnerships, amid interest from companies looking to expand in gene therapy... Calithera Biosciences (CALA), up 8% after announcing results from its randomized placebo-controlled Phase 2 ENTRATA study of telaglenastat in combination with everolimus in patients with advanced renal cell carcinoma... Corteva (CTVA), up 1% after Deutsche Bank analyst David Begleiter upgraded the stock to Buy from Hold and raised his price target for the shares to $32 from $30... Mosaic (MOS), up 3% after BofA Merrill Lynch analyst Steve Byrne upgraded shares to Buy with a price target of $30. LOWER: Paysign (PAYS), down 4% after BTIG analyst Mark Palmer downgraded the stock to Neutral from Buy citing valuation... Endo (ENDP), down 4% after Citi analyst Liav Abraham downgraded shares to Neutral from Buy. While acknowledging the improvement in Endo's underlying business over the past couple of years, the analyst says one "cannot ignore the headwinds" associated with the company's opioid-related litigation... Dow Inc. (DOW), down 1% after BMO Capital Markets analyst John McNulty downgraded the stock to Market Perform from Outperform and lowered his price target for the shares to $52 from $58.